| http://www.w3.org/ns/prov#value | - Dermatologists laud potential cost savings, urge measures to protect patientsBy Jan Bowers, contributing writer, June 03, 2013No one disputes the appeal of the best-case scenario for biosimilars: the marketing of a new class of agents, developed to mimic the biologic drugs used to treat psoriasis and other disorders, that achieve an equivalent safety and efficacy profile at a significantly lower c
|
